Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01565291 · ClinicalTrials.gov registry record · Early Phase 1
A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
A Early Phase 1 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
NCT01565291 is a Early Phase 1 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT01565291, a Early Phase 1 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
A preliminary study to test how florbetapir F 18 (18F-AV-45) acts in the brains and bodies of healthy elderly people and patients with Alzheimer's Disease (AD) by using a positron emission tomography (PET) scanner.
Interventions
- DRUG florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01565291
The ClinicalTrials.gov registry entry for NCT01565291 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which florbetapir F 18 is the first listed.
NCT01565291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01565291 about?
NCT01565291 is a clinical study titled "A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers". A preliminary study to test how florbetapir F 18 (18F-AV-45) acts in the brains and bodies of healthy elderly people and patients with Alzheimer's Disease (AD) by using a positron emission tomography (PET) scanner.
What is the current status of trial NCT01565291?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2007-06. Estimated completion is 2008-01.
What interventions are being tested in trial NCT01565291?
The interventions under investigation include: florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT01565291?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.